CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide (ASO) drug candidates targeting multiple genes linked to neurodegenerative and kidney diseases.
Under the terms of the agreement, CAMP4 will receive an upfront payment of $17.5 million. The company is also eligible for additional development and commercial milestone payments, as well as tiered royalties on future product sales.
CAMP4 will use its proprietary RAP Platform to identify regulatory RNAs controlling the expression of selected gene targets and to generate ASO candidates designed to increase target gene expression. GSK will be responsible for further development and commercialization of any ASO drug candidates arising from the collaboration.
"Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease. Our collaboration with GSK, focused on the rapid identification of novel targets and potential ASO therapeutics that increase the expression of validated genetic targets, underscores the potential of our discovery platform to create transformational medicines for patients," said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4.
CAMP4 Therapeutics shares were down more than 5% in premarket trading after closing at $7.13 on Wednesday, up 1.7%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.